DeutschNewstral
Article
Boston Herald on 2015-10-17 06:12
Shares of Boston biotech dice as FDA halts clinical trial
Related news
Shares in Vancouver biotech firm plunge after FDA finds ‘no clinical benefit’ to COVID-19 drugoregonlive.com- IShould you buy or sell ALLO stock after shares plunge 37% as FDA halts clinical trial?invezz.com
Larimar Therapeutics stock plunges after FDA halts clinical trialbizjournals.com- MAdvaxis shares drop after FDA clinical trial holdmarketwatch.com
- MPuma Biotech shares jump on breast cancer study, FDA applicationmarketwatch.com
- Shares of Cambridge biotech Sarepta crash after harsh FDA reviewbizjournals.com
Archigen Biotech seeks FDA Approval for Rituximab Phase I Clinical Trialsjdsupra.com- Peninsula cell therapy company's stock sheds nearly 40% after-hours as FDA halts clinical trialbizjournals.com
- MSolid Biosciences shares plunge as FDA puts study on clinical holdmarketwatch.com
- MSeattle Genetics shares drop 13% on news of FDA holds on several early-stage clinical trialsmarketwatch.com
- MZiopharm Oncology shares slide 7% premarket after FDA places clinical hold on cancer trialmarketwatch.com
- MJuno shares up 29% as FDA allows resumption of clinical trial for cancer drugmarketwatch.com
- FDA tells Boston biotech to suspend trials of obesity drug after patient deathbizjournals.com
- MKrystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDAmarketwatch.com
- MCrispr, Vertex shares fall after FDA halts sickle-cell disease trialmarketwatch.com
- MOpko Health shares fall as FDA halts approval for new drugmarketwatch.com
- Zafgen shares cut in half after FDA halts diabetes drug trialbizjournals.com
- Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trialbizjournals.com
- MSolid Biosciences shares slide 5% premarket after update of FDA clinical hold on its main product candidatemarketwatch.com
- MSarepta Therapeutics shares dive on safety issues in FDA databasemarketwatch.com